Leonard Zehr, Author at BioTuesdays

Feature

Microbix validating new virology production process

By Len Zehr Microbix Biosystems (TSX:MBX) is validating a new bioreactor manufacturing platform for its world-leading line of viral and bacterial antigens and other virology products ahead of a full roll-out to...

April 5, 2016

Markets

Stifel upgrades Exelixis to buy

Stifel has upgraded Exelixis (NASDAQ:EXEL) to “buy” from “hold” with a price target of $7. The stock closed at $4.05 on Friday. Exelixis is developing small molecule therapies for the treatment of cancer and is focusing...

April 5, 2016

Developments

Piper resumes coverage of NxStage Medical at overweight

Piper Jaffray has resumed coverage of NxStage Medical (NASDAQ:NXTM) with an “overweight” rating and $18.50 price target, down from $23 previously. The stock closed at $14.96 on Wednesday. “We have known the story since...

March 31, 2016

Developments

Oramed gets Indian patent for oral administration of proteins

Oramed Pharmaceuticals’ (NASDAQ:ORMP) patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins” has been granted by the Indian Patent Office. Oramed is seeking to revolutionize the...

March 29, 2016

Developments

HHS ups buprenorphine prescribing to treat opioid addiction

In a speech today, President Obama announced that the Department of Health and Human Services (HHS) has issued a new proposed rule to increase the current patient limit for qualified physicians who prescribe...

March 29, 2016

Feature

Pivot Pharma seeks financing to develop drugs for women’s cancers

By Len Zehr Upstart Pivot Pharmaceuticals (OTCQB:PVOTF), which was launched in the fourth quarter last year, is in talks with investors to raise up to $8-million in 2016 to initiate proof-of-concept studies for one of...

March 29, 2016

Markets

HCW starts Kiadis Pharma at buy

H.C. Wainwright has launched coverage of Kiadis Pharma NV (NXT AM:KDS) of Amsterdam with a “buy” rating and price target of €15. The stock closed at €10 on Friday. “We view Kiadis as an innovator in hematopoietic stem...

March 28, 2016

Markets

HCW assumes coverage of Galmed at buy

H.C. Wainwright analyst, Ed Arce, has assumed coverage of Galmed Pharmaceuticals (NASDAQ:GLMD) with a “buy” rating and $22 price target. The stock closed at $4.44 on Friday. Galmed is focused on the development of a...

March 28, 2016

Developments

Dipexium Pharma receives Locilex patent in Japan

Dipexium Pharmaceuticals (NASDAQ:DPRX) has received a patent in Japan, covering a novel formulation of Locilex, an antimicrobial peptide formulated as a topical cream. The issued patent has an expiry date in June 2033...

March 28, 2016

Markets

Piper Jaffray starts Inogen at neutral

Piper Jaffray has initiated coverage of Inogen (NASDAQ:INGN) with a “neutral” rating and price target of $46. The stock closed at $41.07 on Wednesday. “We truly appreciate the unique technology the company has developed...

March 24, 2016

Author - Leonard Zehr

Microbix validating new virology production process

Stifel upgrades Exelixis to buy

Piper resumes coverage of NxStage Medical at overweight

Oramed gets Indian patent for oral administration of proteins

HHS ups buprenorphine prescribing to treat opioid addiction

Pivot Pharma seeks financing to develop drugs for women’s cancers

HCW starts Kiadis Pharma at buy

HCW assumes coverage of Galmed at buy

Dipexium Pharma receives Locilex patent in Japan

Piper Jaffray starts Inogen at neutral

Subscribe